POSC279 The Impact of a Reassessment Due to New Scientific Findings on the Additional Benefit and on the Reimbursed Price of Pharmaceutical Products According to §35A Sgb V in Germany
Abstract
Authors
C Schmalhofer I Ernst T Fischer K Strimitzer D Bonduelle